7,376.86

+23.13

+0.31%

51,285.73

-237.33

-0.46%

24,579.42

+264.43

+1.09%

2,754.11

+24.22

+0.89%

4.8590

+0.0220

+0.45%

25.64

-2.54

-9.01%

4,074.90

-38.60

-0.94%

75,720.64

+44.18

+0.06%

Crude Oil Dec 26

90.83

+0.31

+0.34%

US Private Equity

10,772.76

+11.83

+0.11%

NasdaqGS - Nasdaq Real Time Price USD

Arbutus Biopharma Corporation (ABUS)

3.6550 -0.0150 (-0.41%)

At close: November 6 at 4:00:01 PM EST

3.6500 -0.0050 (-0.14%)

After hours: November 6 at 4:50:29 PM EST

Trade ABUS on Coinbase

Loading Chart for ABUS

Chart Range Bar

Interval:

In partnership with ChartIQ

MRNA Q3 Earnings Beat on COVID Sales, Raises '26 Outlook, Stock Rises

MRNA Q3 Earnings Beat on COVID Sales, Raises '26 Outlook, Stock Rises

Arbutus Announces FDA Clinical Hold is Lifted on IND Application for AB-101, an Oral PD-L1 Inhibitor

Arbutus Announces FDA Clinical Hold is Lifted on IND Application for AB-101, an Oral PD-L1 Inhibitor

Arbutus Announces Final Results of Its US$230 Million Modified “Dutch Auction” Tender Offer

Arbutus Announces Final Results of Its US$230 Million Modified “Dutch Auction” Tender Offer

Arbutus Announces Preliminary Results of Its US$230 Million Modified “Dutch Auction” Tender Offer

Arbutus Announces Preliminary Results of Its US$230 Million Modified “Dutch Auction” Tender Offer

Arbutus Biopharma shares jump after unveiling $230 million share buyback plan

Arbutus Biopharma shares jump after unveiling $230 million share buyback plan

Arbutus Announces Intent to Repurchase Up to US$230 Million of its Common Shares Through Modified “Dutch Auction” Tender Offer

Arbutus Announces Intent to Repurchase Up to US$230 Million of its Common Shares Through Modified “Dutch Auction” Tender Offer

Could Arbutus Biopharma Corporation (ABUS) Turn its Moderna, Inc. (MRNA) Settlement Into a Lasting Biotech Advantage?

Could Arbutus Biopharma Corporation (ABUS) Turn its Moderna, Inc. (MRNA) Settlement Into a Lasting Biotech Advantage?

Arbutus, Sanofi escalate mRNA patent fights; InnoCare’s TYK2 contender advances

Arbutus, Sanofi escalate mRNA patent fights; InnoCare’s TYK2 contender advances

ABUS Stock On Track For Best Day In About Two Months — What’s The Moderna Connection?

ABUS Stock On Track For Best Day In About Two Months — What’s The Moderna Connection?

Arbutus Initiates International Patent Infringement Enforcement Actions Against Pfizer and BioNTech, Receives First Payment From Moderna Settlement Agreement and Announces Intent to Return Capital to Shareholders

Arbutus Initiates International Patent Infringement Enforcement Actions Against Pfizer and BioNTech, Receives First Payment From Moderna Settlement Agreement and Announces Intent to Return Capital to Shareholders

Arbutus Biopharma (ABUS) Joins Russell Defensive Indexes And Exits Value Benchmarks

Arbutus Biopharma (ABUS) Joins Russell Defensive Indexes And Exits Value Benchmarks

Mobilize your Website

View Site in Mobile | Classic

Share by: